Blocking gene boosts T-cell attacks on chronic hepatitis B virus and tumors

A probe squad led by Professor Zhou Xuyu from the Institute of Microbiology of the Chinese Academy of Sciences (CAS), successful collaboration with researchers from Beijing Ditan Hospital and Capital Medical University, has identified ANKRD11 arsenic a cardinal regulator that reduces the enactment of CD8+ T cells during chronic hepatitis B microorganism (HBV) corruption and cancer. The researchers recovered that ANKRD11 suppresses the AP-1 signaling pathway, which usually helps CD8+ T cells equine effectual responses against infections and tumors.